carditis, sarcoidosis, amyloidosis or other metabolic heart disease. Patients with secondary DCM and those with infectious disease were excluded from the study. Patients with renal failure (serum creatinine >2 mg/dl) were also excluded. Cardiac catheterization was performed after improvement of the CHF symptoms. The investigation conformed to the principles outlined in the Declaration of Helsinki. Written informed consent was given by all patients before participating in the present study, and the protocol was approved by the institutional Human Investigations Committee.
Study Protocol
All patients were premedicated with an oral dose of diazepam (5 mg) and rested in bed for at least 20 min. Right-sided cardiac catheterization was performed using a Swan-Ganz catheter. Blood samples for measuring plasma levels of IL-6, BNP, norepinephrine (NE) and endothelin (ET)-1 and serum hsCRP were collected from the aortic root. Left ventriculography was performed using contrast medium after obtaining hemodynamic measurements and blood samples. All patients were followed for more than 12 months (mean follow-up 42 months).
Measurements of Cytokines and Neurohumoral Factors
Blood for measurement of the plasma levels of BNP, IL-6 and ET-1 was transferred to a chilled tube containing EDTA (1 mg/ml) and aprotinin (500 kallikrein inactivator units/ml). NE was transferred to a chilled tube containing EDTA (1 mg/ml), then centrifuged at 3,000 rpm for 15 min at 4°C, and the plasma thus obtained was stored at -30°C until assay. Plasma BNP concentrations were measured with a specific immunoradiometric assay kit for human BNP (Shionogi, Osaka, Japan) as previously reported. 3 IL-6 measurement was performed using a commercially available immunoassay kit (Quantikine HS, R&D Systems, Minneapolis, MN, USA) as previously reported. 16 ET-1 levels were measured by radioimmunoassay as previously reported. 21 Plasma NE concentrations were measured by high-performance liquid chromatography.
Blood for measurement of the serum level of hsCRP was transferred to a chilled tube, then centrifuged at 3,000 rpm for 15 min at 4°C, and the serum thus obtained was stored at -30°C until assay. Serum hsCRP was measured by a sensitive nephelometric assay (Behring Diagnostics, Marburg, Germany).
Statistical Analysis
All results are expressed as the mean ± SEM. Univariate analysis was performed using Student's t-test. Categorical data were compared against a chi-square distribution. The prognostic value of the variables was tested in a Cox proportional hazards regression analysis. A Kaplan-Meier analysis was performed on the cumulative rates of survival in patients with CHF stratified into 4 groups based on median plasma levels of BNP and normal concentration of hsCRP, and the differences between the survival curves were analyzed using a log-rank test. To determine whether the serum hsCRP concentration seen in our CHF patients was an independent prognostic factor or only reflected the importance of other factors, 13 variables were entered into a Cox proportional hazard analysis. Linear regression analysis was used to determine the relationship between continuous variables. BNP, hsCRP and IL-6 were highly skewed and therefore logarithmically transformed in all analyses. A value of p<0.05 was considered significant. (Table 1) The subjects were 68 men and 16 women ranging in age from 16 to 80 years old (mean: 55 years). Twelve patients were classified according to the standards of the New York Heart Association (NYHA) as functional class I, 39 as class II, 30 as class III and 3 as class IV. At entry into the present study, 64 patients were treated with furosemide, 56 with spironolactone, 62 with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin-receptor blockers (ARB), 44 with digitalis, 27 with -blockers, 10 with statin and 30 with aspirin. After 6 months follow up, 71 patients were receiving ACEI or ARB (89.8%), and 57 patients were receiving -blockers (72.1%).
Results

Patient Characteristics and Hemodynamic Data
Plasma Concentrations of Neurohumoral Factors and Cytokines in Patients With DCM
In the present study, we defined NYHA functional class I or II as mild CHF, III or IV as severe CHF. In CHF patients with DCM, plasma levels of BNP, NE, ET-1, serum hsCRP and pulmonary capillary wedge pressure (PCWP) were increased with the severity of CHF (Fig 1) . In the present study, cardiac events were defined as cardiac death or hospitalization for worsening heart failure. In patients with cardiac events, plasma BNP, NE, serum hsCRP and PCWP were higher and the left ventricular ejection fraction (LVEF) was lower than those in patients without cardiac events. There were no significant differences of plasma IL-6 and ET-1 levels between the patients with cardiac events and those without cardiac events (Fig 2) .
Comparisons Between Serum hsCRP and Hemodynamic Date or Neurohumoral Factors
Serum log hsCRP concentration significantly correlated with plasma log IL-6 (R=0.455, p<0.0001). However, there was no relationship between serum log hsCRP and plasma log BNP. There was no relationship between log hsCRP and LVEF (Fig 3) . According to stepwise multivariate analyses between neurohumoral factors and hemodynamics, only log IL-6 showed an independent and significant positive relationship with log hsCRP (Table 2) .
Univariate and Multivariate Predictors of Cardiac Events
During the long-term follow-up period, 23 patients had cardiac events and 18 patients died of cardiac causes. Thirteen clinical, neurohumoral and hemodynamic variables were analyzed using univariate and stepwise multivariate Cox proportional hazards regression analyses. Using univariate analyses, NYHA class, LVEF, PCWP, plasma NE, log BNP and serum hsCRP >1 mg/L were significant predictors of cardiac events. According to stepwise multivariate analyses, log BNP (p=0.007) and hsCRP >1 mg/L (p= 0.008) were significant independent predictors of cardiac events ( Table 3 ). The relative risk ratio of log BNP was 3.9 (95% confidence interval (CI), 1.4-9.6), and that of hsCRP >1 mg/L was 3.4 (95% CI, 1.4-8.1). Log BNP (p=0.013) and hsCRP >1 mg/L (p=0.021) were significant independent predictors of mortality (Table 4 ). The relative risk ratio of log BNP was 4.4 (95% CI, 1.3-12.2), and that of hsCRP >1 mg/L was 3.3 (95% CI, 1.2-9.0).
Kaplan-Meier Lifetime Analysis
Patients were stratified into 4 groups based on normal serum concentration of hsCRP (1 mg/L) and median plasma concentration of BNP (110 pg/ml), and cumulative survival curves were constructed by Kaplan-Meier event methods. The normal hsCRP level is defined as a low-risk group by both the American Heart Association and the Centers for Disease Control and Prevention. 22 From receiver operating characteristic curve analysis, hsCRP >1 mg/L had a sensitivity of 60.8% and a specificity of 72.2%, and BNP >110 pg/ml had a sensitivity of 78.2% and a specificity of 57.4% for cardiac events. hsCRP >1 mg/L had a sensitivity of 61.1% and a specificity of 68.2%, and BNP >110 pg/ml had a sensitivity of 77.7% and a specificity of 54.6% for mortality (Fig 4) . Survival rates, as evaluated using Kaplan-Meier event analysis, were significantly higher in patients with serum hsCRP concentration <1 mg/L and BNP <110 pg/ml than in patents with hsCRP >1 mg/L and BNP >110 pg/ml (Fig 5) . The hazard ratio of patients with BNP >110 pg/ml and hsCRP >1 mg/L was 15.8 (95% CI, 1.9-127.2) compared to those with BNP <110 pg/ml and hsCRP <1 mg/L for cardiac death.
Discussion
The prognostic value of hsCRP has been established in patients with atherothrombotic disease 23, 24 and in the present study, we tested its role in CHF patients with nonischemic DCM. There was no significant correlation between serum hsCRP level and plasma BNP concentration, a possible marker of hemodynamic overload. However, both hsCRP >1 mg/L and BNP were independent prognostic predictors on measurement of hemodynamics and plasma levels of NE, ET-1, and IL-6. Moreover, the hazard ratio for cardiac death in patients with BNP >110 pg/ml and hsCRP >1 mg/L was 15.8 compared with that of those with BNP <110 pg/ml and hsCRP <1 mg/L, suggesting that the combination of measurements of hsCRP and BNP is useful for the management of CHF caused by DCM.
Why is hsCRP an Independent Prognostic Predictor in Patients With DCM?
The exact reason for the significant prognostic role of hsCRP in CHF patients with nonischemic DCM remains unknown. Several possibilities are postulated: (1) a high level of hsCRP may reflect an activated immune response involving the myocardium; or (2) CRP itself may cause endothelial dysfunction, as well as being a potential prognostic predictor, thereby causing deterioration of CHF. Expressions of the proinflammatory cytokine tumor necrosis factor and IL-6 have been described in patients with CHF, in both the plasma and in the myocardium, 5, 16, 17, 25, 26 and these cytokines stimulate the production of CRP mainly produced by hepatocytes. Recently, CRP has been found in other tissues, such as atherosclerotic plaque and human coronary artery smooth muscle cells. 27 Therefore, a high level of hsCRP may reflect an activated immune response in patients with DCM.
CRP is not only a biomarker of inflammation but also a mediator of endothelial dysfunction via stimulation of IL-6, increased ET-1 25 and decreased NO production. 19, 20 Previous study has shown that systemic inflammation may contribute to endothelial dysfunction. 28 Several recent studies demonstrated that endothelial dysfunction influences the pathogenesis and prognosis of CHF. 29, 30 Therefore, CRP itself causes endothelial dysfunction, a potential prognostic predictor, and thereby causes deterioration of CHF caused by DCM.
Comparison of hsCRP, IL-6 and BNP as Predictors of CHF
We have reported that the plasma IL-6 level is an independent prognostic indicator, as well as an additional risk factor for mortality in CHF patients. 16, 17 In the present study, hsCRP was a stronger predictor than IL-6, partly because IL-6 has a short half-life. In contrast, CRP has a serum half-life of 18-20 h. Furthermore, the assay for hsCRP has been standardized across many commercial platforms, whereas those for other cytokines remain poorly standardized, and methodological issues limit their use despite consistent population-based data.
Both CRP and BNP were reported as important prognostic markers of heart failure in a study of a communitybased elderly population. 31 In the present study, we demonstrated for the first time that both BNP and hsCRP, which can be measured in standard clinical laboratories, are independent predictors of prognosis in CHF patients. The finding that hsCRP is more useful than IL-6 is good news for clinical practice, because the measurement of hsCRP is universally standardized and costs less than that of IL-6.
Study Limitations
We evaluated hsCRP and other neurohumoral factors using only one point sampling when patient conditions were relatively stable. We could not observe the time course of neurohumoral factors after treatment for CHF. Further studies of the prognostic role of hsCRP before and after standard therapy for CHF are needed.
The present study is also limited by its modest sample size. Larger studies are needed to confirm whether the hsCRP level itself is a useful prognostic marker for CHF with DCM.
Conclusions
hsCRP is a useful prognostic marker that is independent of hemodynamics and BNP, and the combination of hsCRP and BNP may be useful in the management of CHF patients with DCM.
